Health Commission hears how Bay Area is joining major vaccine trials and plans outreach to reach communities of color

Dr. Susan Buchbinder, speaking for the local CoVPN site network, told the Health Commission the department and partners are preparing to run and recruit for large phase‑3 vaccine trials and are prioritizing community engagement to enroll populations most affected by COVID-19.

"So what is it that we're hoping that a COVID vaccine could do?" Buchbinder asked rhetorically during her Sept. 15 presentation. She described objectives ranging from reduced disease severity to lowered transmission and noted most vaccine candidates target the virus's spike protein.

Buchbinder outlined how vaccine testing proceeds through preclinical and phased human trials and said acceleration efforts like Operation Warp Speed are shortening gaps between phases without skipping safety steps. She highlighted the NIH COVID Prevention Network (CoVPN) and said the Bay Area will host several CoVPN sites, including a San Francisco DPH site and a UCSF site at Zuckerberg San Francisco General.

She described the AstraZeneca phase‑3 design that began Aug. 28, 2020: roughly 30,000 global participants with a 2:1 randomization (20,000 vaccine : 10,000 placebo) and planned enrollment targets for local sites. Buchbinder also addressed a widely reported safety pause tied to an unexplained neurologic illness in a U.K. participant: "It's not entirely clear whether it is or not. The evaluation is currently underway," she said, noting regulators in some countries had reopened studies while U.S. review was ongoing.

Commissioners sought demographic breakdowns of the 9,000-plus local volunteers in the recruitment registry; Buchbinder said sign-ups skewed toward white and English speakers but that the enrollment pool allows the city to prioritize recruitment from underrepresented groups and that community outreach and Spanish-language materials are being used.

Buchbinder flagged two programmatic risks: community hesitancy and the potential mismatch between the populations most harmed by COVID-19 and those most willing to enroll. She said CoVPN has launched town halls, listening sessions and faith-based outreach and has a local website (wecanbeatcovid.org and a Spanish site, combatimoscovid.org) to register volunteers.

Commissioners asked how local public-health authorities will be involved in vaccine distribution once efficacy is established. Buchbinder said she expects states and local health departments will play a major role in prioritization and distribution and that the department is starting operational planning alongside influenza vaccination work to exercise distribution logistics.

What's next: DPH and CoVPN sites will continue targeted outreach to improve trial diversity, provide requested demographic sign-up data to the commission, and coordinate with regional health officers on distribution planning once a vaccine is available.